Ed Schutter
President & CEO, Arbor Pharmaceuticals

Ed Schutter is a thirty year veteran of the pharmaceutical industry currently serving as President and CEO of Arbor Pharmaceuticals. Arbor was generating about $2.5 million in annualized sales when it was acquired in March 2010 by an investor group led by Ed, Jason Wild and Allen Chao. The company revenue reached $260 million in 2014. Arbor currently markets seventeen FDA approved products and focuses its brand business primarily in the cardiovascular, hospital, and pediatric markets. Arbor’s generic products are marketed through its wholly owned subsidiary, Wilshire Pharmaceuticals. The company has approximately 400 employees and has a pipeline of five branded (NDAs) and thirty-five generic (ANDAs) products in development.

Prior to Arbor, Ed served as President of Sciele Pharmaceuticals (SCRX) which was sold to Shionogi & Co. Ltd. in 2008 for $1.4 billion.  Prior to his Sciele experience, Ed served as VP of Global Business development at Solvay Pharmaceuticals based in Basel, Switzerland. He also held several senior management roles at the U.S. subsidiary of Solvay during his twenty years with the organization. Ed began his pharmaceutical career with Reid-Provident Laboratories, a small entrepreneurial pharmaceutical company based in Atlanta, Ga.

Ed was also a co-founder of North Hampton Pharmaceuticals which later changed its name to Ventrus Biosciences, a Nasdaq listed company.  In addition to his board duties with Arbor Pharmaceuticals, Ed is on the Board of Trustees for Mercer University, Chairman of the Board of Georgia Bio, a board member of Knight Therapeutics Inc. (GUD.TO), a member of the Emory University New Venture Advisory Board, and a founding member and Executive Director of the Atlanta based Bio/Med Investor Network Inc.  Ed holds a Bachelor degree in Pharmaceutical Sciences from Mercer University, a Masters of Business Administration from Kennesaw State University and has also completed post graduate work in international business at Nyenrode University in the Netherlands.  Ed is currently an angel investor in several companies, including biotech, branded and generic pharmaceutical companies.